CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
CASTLE BIOSCIENCES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$32.16+0.20 (+0.64%)
Close on Oct 19, 2026
- Market cap
- $977.78M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Share price
+$10.02 (+45.28%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
CASTLE BIOSCIENCES INC grew revenue 3.2% to $357.28M over the twelve months to Jun 30, 2026. Free cash flow was -$489.00K, down 101.4% from a year earlier.
Revenue
$357.28M
+3.2% vs. a year earlier
Operating income
-$32.11M
TTM Q2 2026
Free cash flow
-$489.00K
-101.4% vs. a year earlier
EPS, diluted
-$0.66
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $977.78M
- P/E ratio
- –
- Price to sales
- 2.74
- Price to book
- 2.08
- Dividend yield
- 0.00%
- Free cash flow yield
- -0.05%
Fundamentals
- Revenue
- $357.28M
- Net income
- -$19.42M
- EPS, diluted
- -$0.66
- Free cash flow
- -$489.00K
- Book value per share
- $15.46
- Diluted shares
- 30M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
$357.28M+3.2% YoY
Gross profit
$276.03M-1.6% YoY
Operating income
-$32.11M
Net income
-$19.42M
EPS, diluted
-$0.66
Free cash flow
-$489.00K-101.4% YoY
Reported periodTrailing twelve months